VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1’s hydrophobic fusion peptide gp41 preventing the virus from inserting itself into a host cell’s membrane to initiate an infection.
This page contains content from the copyrighted Wikipedia article "VIR-576"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
